Hepatitis B and HIV/AIDS coinfections are common globally due to their similar mode of transmission. Since HIV infection modifies the course of HBV infection by increasing the rate of chronicity, prolonging HBV viremia, and increasing liver disease-associated deaths, individuals with coinfection of both diseases have a higher tendency of developing cirrhosis of the liver, higher levels of HBV DNA, reduced rate of clearance of the hepatitis B e antigen (HBeAg), and more likely to die than an individual with a single infection. This nature of HBV-HIV/AIDS coinfection motivated us to conduct this study. In this paper, we proposed and rigorously analyzed a deterministic mathematical model with the aim of investigating the effect of vaccination against hepatitis B virus and treatment for all infections on the transmission dynamics of HBV-HIV/AIDS coinfection in a population. We proved that the solutions of the submodels and the coinfection model are positive and bounded. The models are studied qualitatively using the stability theory of differential equations, and the effective reproduction numbers of the models are derived using the next generation matrix method. Stability of the equilibria of the submodels and the coinfection model is analyzed using Routh-Hurwitz criteria. The disease-free and endemic equilibria of the submodels and the coinfection model are computed, and both local and global asymptotic stability conditions for those equilibria are discussed. We performed a sensitivity analysis to illustrate the influence of different parameters on the effective reproduction number of HBV-HIV/AIDS coinfection model, and we identified the most sensitive parameters are ω B and ω H , which are the effective contact rates for HBV and HIV transmission, respectively. The numerical simulation of the model is done using MATLAB, and the findings from the simulations are discussed. It is observed that if the vaccination and treatment rates are increased, then the number of individuals susceptible to both infections and HBV-HIV/AIDS coinfection decreases and even falls to zero over time. Hence, it is concluded that vaccination against hepatitis B virus infection, treatment of hepatitis B and HIV/AIDS infections, and HBV-HIV/AIDS infection at the highest possible rate is very essential to control the spread of HBV-HIV/AIDS coinfection as an important public health problem.
In this study, we analyzed the effect of mother-to-child transmission (MTCT) of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) on the transmission dynamics of their coinfection to make a recommendation based on reasons to public health sector, policy makers, and programme implementers. We proved that the solutions of the sub and full models are positive and bounded. The effective reproduction numbers of the models are derived using the next generation matrix method. The disease-free and endemic equilibria of the submodels and the coinfection model are computed, and the stability of those equilibria is analyzed using Routh-Hurwitz criteria after computing the associated effective reproduction numbers. We performed a sensitivity analysis to show the influence of different parameters on the effective reproduction number of HBV-HIV/AIDS coinfection model, and we identified the most sensitive parameters are τ 2 and α 1 , which are the rate of MTCT of HIV and treatment rate for HBV infected class, respectively. The numerical simulation of the model is done using MATLAB and the findings from the simulations are discussed. From the results of numerical simulations, we observed that an increase in the rates of MTCT of HBV and HIV exacerbated HBV-HIV/AIDS coinfection, while a decrease in the rates of MTCT of these infections would decline the number of cases, minimize the spread, and help to eliminate HBV-HIV/AIDS coinfection from the society gradually.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.